13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001953107
Total reported value
$345.4M
$345.4M
7 檔
92.6%
At the close of Q1 2026, Enavate Sciences GP, LLC disclosed equity holdings valued at approximately $345.4M, spread across 7 reported holdings.
In Q1 2026, Enavate Sciences GP, LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 0 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SION | Sionna Therapeutics Inc | Stock-Other | 28.26% | +3.30% | — | |
| 2 | IMNM | Immunome Inc | Stock-Other | 22.48% | -0.31% | -24.22% | |
| 3 | ZBIO | Zenas Biopharma Inc | Stock-Other | 21.80% | +7.00% | — | |
| 4 | CMPX | Compass Therapeutics Inc | Stock-Other | 11.72% | -6.78% | — | |
| 5 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 6.69% | -0.89% | — | |
| 6 | UPB | Upstream Bio Inc | Stock-Other | 6.30% | -1.37% | — | |
| 7 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 2.75% | -0.95% | -27.83% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SION | Sionna Therapeutics Inc | +8.1% | — | Unchanged |
| 2 | CMPX | Compass Therapeutics Inc | +3.5% | — | Unchanged |
| 3 | IMNM | Immunome Inc | +2.3% | -24.22% | Trim |
| 4 | BBOT | Bridgebio Oncology Therapeut | +0.2% | — | Unchanged |
| 5 | CAMP | Camp4 Therapeutics CORP | -0.9% | -27.83% | Trim |
| 6 | ZBIO | Zenas Biopharma Inc | -6.3% | — | Unchanged |
| 7 | UPB | Upstream Bio Inc | -6.9% | — | Unchanged |
According to official SEC Form 13F filings, Enavate Sciences GP, LLC reported a total U.S. public equity portfolio value of $345.4M across 7 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SION, IMNM, ZBIO) accounted for 92.6% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
IMNM
前期市值: $102.4M
During Q1 2026, Enavate Sciences GP, LLC's top holdings by market value included SION (28.3%)、IMNM (22.5%)、ZBIO (21.8%). The largest single position, SION, represented 28.3% of total portfolio value.
In Q1 2026, Enavate Sciences GP, LLC made 2 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 2 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.